These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38410201)

  • 1. Preparation of hepatocellular carcinoma mRNA vaccines based on potential tumor targets and immunophenotypes.
    Wang HK; Xu XH; Wang SM; Zhang HY
    Transl Cancer Res; 2024 Jan; 13(1):173-190. PubMed ID: 38410201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development.
    Lu TL; Li CL; Gong YQ; Hou FT; Chen CW
    World J Gastrointest Oncol; 2023 Oct; 15(10):1717-1738. PubMed ID: 37969406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination.
    You W; Ouyang J; Cai Z; Chen Y; Wu X
    Front Immunol; 2022; 13():827506. PubMed ID: 35874675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying Potential Tumor Antigens and Antigens-Related Subtypes in Hepatocellular Carcinoma for mRNA Vaccine Development.
    Liao W; Shi Z; Tang H; Wu T; Zhang C; He Y; Zou R; Wang L
    J Oncol; 2022; 2022():6851026. PubMed ID: 36072981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune signature-based hepatocellular carcinoma subtypes may provide novel insights into therapy and prognosis predictions.
    Zheng Q; Yang Q; Zhou J; Gu X; Zhou H; Dong X; Zhu H; Chen Z
    Cancer Cell Int; 2021 Jun; 21(1):330. PubMed ID: 34193146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
    Huang X; Zhang G; Tang T; Liang T
    Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
    Mo Z; Liu D; Rong D; Zhang S
    Front Immunol; 2021; 12():611058. PubMed ID: 33679749
    [No Abstract]   [Full Text] [Related]  

  • 8. Dissection of tumor antigens and immune landscape in clear cell renal cell carcinoma: Preconditions for development and precision medicine of mRNA vaccine.
    Hu J; Mo Z
    Math Biosci Eng; 2023 Jan; 20(2):2157-2182. PubMed ID: 36899527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
    Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
    Front Immunol; 2021; 12():738435. PubMed ID: 34603319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development.
    Wu C; Qin C; Long W; Wang X; Xiao K; Liu Q
    J Big Data; 2022; 9(1):92. PubMed ID: 35855914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development.
    Fu J; Chen F; Lin Y; Gao J; Chen A; Yang J
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):4047-4061. PubMed ID: 36038676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Molecular Subtyping Scheme Based on In Silico Analysis of Cuproptosis Regulator Gene Patterns Optimizes Survival Prediction and Treatment of Hepatocellular Carcinoma.
    Jiang H; Chen H; Wang Y; Qian Y
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioinformatics analyses for the identification of tumor antigens and immune subtypes of gastric adenocarcinoma.
    Wei S; Sun Q; Chen J; Li X; Hu Z
    Front Genet; 2022; 13():1068112. PubMed ID: 36579327
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development.
    Lu T; Xu R; Wang CH; Zhao JY; Peng B; Wang J; Zhang LY
    Front Genet; 2022; 13():853113. PubMed ID: 35734437
    [No Abstract]   [Full Text] [Related]  

  • 15. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
    Cai J; Zhou M; Xu J
    World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
    Gao S; Zhang L; Wang H
    Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of tumor-specific neoantigens and immune clusters of hepatocellular carcinoma for mRNA vaccine development.
    Li YF; Hou QQ; Zhao S; Chen X; Tang M; Li L
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):623-637. PubMed ID: 36239794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
    Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
    Front Immunol; 2021; 12():709986. PubMed ID: 34512630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
    Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
    Front Immunol; 2022; 13():773264. PubMed ID: 35185876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
    Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
    Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.